Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis
Open Access
- 30 April 2026
- journal article
- review article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 417, 578945
Abstract
No abstract availableKeywords
Funding Information
- Hamad Medical Corporation
- Qatar National Library
This publication has 20 references indexed in Scilit:
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderMultiple Sclerosis and Related Disorders, 2022
- Neuromyelitis opticaNature Reviews Disease Primers, 2020
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialThe Lancet Neurology, 2020
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialThe Lancet, 2019
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum DisorderNew England Journal of Medicine, 2019
- What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patientsJournal of Neurology, 2017
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2013
- Aquaporin water channels in the nervous systemNature Reviews Neuroscience, 2013
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004